Mizuho Securities Reiterates TCR2 Therapeutics (TCRR) at Buy, $20 PT, Sees Meaningful Upside on Phase 2 Data, Views 2023 Readout as Another Major Opportunity
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $20.00 price target on TCR2 Therapeutics (NASDAQ: TCRR), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
